Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Lx1606
2. Telotristat
1. 1137608-69-5
2. Lx1606 Hippurate
3. Telotristat Ethyl Hippurate
4. Lx1032 Hippurate
5. Telotristat Etiprate [usan]
6. Lx 1606 Hippurate
7. Lx1606 (hippurate)
8. 1137608-69-5 (etiprate)
9. Lx-1606 Hippurate
10. 3t25u84h4u
11. Telotristat Etiprate (usan)
12. 2-benzamidoacetic Acid, ((s)-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)-1-ethoxy-1-oxopr
13. (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate 2-benzamidoacetate .
14. 4-[2-amino-6-[(1r)-1-[4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]-4-pyrimidinyl]-l-phenylalanine Ethyl Ester N-benzoylglycine Salt
15. Telotristat Etiprate (lx 1606 Hippurate)
16. Unii-3t25u84h4u
17. Lx 1032 Hippurate
18. Lx-1032 Hippurate
19. Chembl3348963
20. Telotristat Etiprate [mi]
21. Amy38702
22. Ex-a1619
23. S2173
24. Telotristat Etiprate [who-dd]
25. Akos027250730
26. Ccg-270440
27. Cs-0429
28. Ncgc00346476-01
29. (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate Hippurate
30. 4-[2-amino-6-[(1r)-1-[4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]-4-pyrimidi
31. Ac-30898
32. Hy-13055
33. Telotristat Etiprate [orange Book]
34. Sw219281-1
35. D09975
36. Q27257995
37. 2-benzamidoacetic Acid, ((s)-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)-1-ethoxy-1-oxopropan-2-yl)amide Salt
38. 2-benzamidoacetic Acid;ethyl (2s)-2-amino-3-[4-[2-amino-6-[(1r)-1-[4-chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]pyrimidin-4-yl]phenyl]propanoate
39. Ethyl 4-(2-amino-6-((1r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pryrimidin-4-yl)-l-phenylalaninate N-benzoylglycinate (1:1)
40. L-phenylalanine, 4-(2-amino-6-((1r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)- 2,2,2-trifluoroethoxy)-4-pryrimidinyl)-, Ethyl Ester, Compd. With N-benzoylglycine (1:1)
Molecular Weight | 754.2 g/mol |
---|---|
Molecular Formula | C36H35ClF3N7O6 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 13 |
Exact Mass | 753.2289440 g/mol |
Monoisotopic Mass | 753.2289440 g/mol |
Topological Polar Surface Area | 198 Ų |
Heavy Atom Count | 53 |
Formal Charge | 0 |
Complexity | 1020 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 1 | |
---|---|
Drug Name | XERMELO |
Active Ingredient | TELOTRISTAT ETIPRATE |
Company | LEXICON PHARMS INC (Application Number: N208794. Patents: 7553840, 7709493, 7968559, 8193204, 8653094) |
Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
Treatment of carcinoid syndrome
A16A
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
97
PharmaCompass offers a list of Telotristat Etiprate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Telotristat Etiprate manufacturer or Telotristat Etiprate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Telotristat Etiprate manufacturer or Telotristat Etiprate supplier.
PharmaCompass also assists you with knowing the Telotristat Etiprate API Price utilized in the formulation of products. Telotristat Etiprate API Price is not always fixed or binding as the Telotristat Etiprate Price is obtained through a variety of data sources. The Telotristat Etiprate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A AKOS027250730 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AKOS027250730, including repackagers and relabelers. The FDA regulates AKOS027250730 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AKOS027250730 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of AKOS027250730 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A AKOS027250730 supplier is an individual or a company that provides AKOS027250730 active pharmaceutical ingredient (API) or AKOS027250730 finished formulations upon request. The AKOS027250730 suppliers may include AKOS027250730 API manufacturers, exporters, distributors and traders.
click here to find a list of AKOS027250730 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing AKOS027250730 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for AKOS027250730 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture AKOS027250730 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain AKOS027250730 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a AKOS027250730 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of AKOS027250730 suppliers with NDC on PharmaCompass.
AKOS027250730 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of AKOS027250730 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right AKOS027250730 GMP manufacturer or AKOS027250730 GMP API supplier for your needs.
A AKOS027250730 CoA (Certificate of Analysis) is a formal document that attests to AKOS027250730's compliance with AKOS027250730 specifications and serves as a tool for batch-level quality control.
AKOS027250730 CoA mostly includes findings from lab analyses of a specific batch. For each AKOS027250730 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
AKOS027250730 may be tested according to a variety of international standards, such as European Pharmacopoeia (AKOS027250730 EP), AKOS027250730 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AKOS027250730 USP).